Skip to main content
Home
  • About
    • Board of Directors
    • Our Staff
    • Annual Reports
    • Policies
    • Careers
  • Programs
    • Research
      • IMEDS
      • Post Market Research
      • RAISE
      • Real World Data
    • Antimicrobial Use Data in Food Animals
    • Expanded Access Navigator
    • Food & Nutrition
    • Substance Use Disorders
    • FDA Operational Evaluation
    • FDA Patient Listening Sessions
    • COVID-19 Hub
    • Fellowship
  • News and Events
    • 2023 Annual Public Meeting
    • Innovations in Regulatory Science Awards
    • News
    • Events
    • Publications
  • eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • Board of Directors
    • Our Staff
    • Annual Reports
    • Policies
    • Careers
  • Programs
    • Research
      • IMEDS
      • Post Market Research
      • RAISE
      • Real World Data
    • Antimicrobial Use Data in Food Animals
    • Expanded Access Navigator
    • Food & Nutrition
    • Substance Use Disorders
    • FDA Operational Evaluation
    • FDA Patient Listening Sessions
    • COVID-19 Hub
    • Fellowship
  • News and Events
    • 2023 Annual Public Meeting
    • Innovations in Regulatory Science Awards
    • News
    • Events
    • Publications
  • eRequest

News

Breadcrumb

  1. Home
  2. News and Events
  3. FDA Approves Opioid Overdose Treatment Narcan for Over-the-Counter Sales - Rolling Stone
  • facebook
  • twitter
  • email
  • print

FDA Approves Opioid Overdose Treatment Narcan for Over-the-Counter Sales - Rolling Stone

AN OVER-THE-COUNTER NASAL spray version of Narcan, the medication used to reverse the effects of an opioid overdose, was officially approved by the Food and Drug Administration today, March 29. 

Read more

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
admin@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA